Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

21.78 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

April 30, 2025

Via ACCESS Newswire

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

April 29, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest

April 28, 2025

Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is an undervalued gem with solid fundamentals. ↗

April 25, 2025

Uncover the potential of AMPHASTAR PHARMACEUTICALS IN, an undervalued stock. NASDAQ:AMPH maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024

February 27, 2025

Via ACCESS Newswire

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About

April 24, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

2 Reasons to Like AMPH and 1 to Stay Skeptical

April 15, 2025

What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results...

Via StockStory

Topics Supply Chain

Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

April 03, 2025

Via ACCESS Newswire

International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award

March 28, 2025

Via ACCESS Newswire

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), an undervalued stock with good fundamentals. ↗

March 27, 2025

Take a closer look at AMPHASTAR PHARMACEUTICALS IN , a remarkable value stock. NASDAQ:AMPH excels in fundamentals and maintains a very reasonable valuation.

Via Chartmill

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference

March 05, 2025

Via ACCESS Newswire

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

March 05, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds ↗

February 28, 2025

Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth.

Via Benzinga

Amphastar: Earnings Miss, Margins Drop ↗

February 28, 2025

Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.

Via The Motley Fool

Topics Earnings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%

February 27, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow

February 26, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Via StockStory

Top 2 Health Care Stocks That May Rocket Higher This Month ↗

February 21, 2025

Via Benzinga

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

February 21, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025

February 20, 2025

Via ACCESS Newswire

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

February 19, 2025

Via StockStory

Topics Artificial Intelligence Intellectual Property

NASDAQ:AMPH is an undervalued gem with solid fundamentals. ↗

February 18, 2025

AMPHASTAR PHARMACEUTICALS IN is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:AMPH showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

February 14, 2025

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

February 13, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

February 04, 2025

Via Benzinga

Investors should take notice of NASDAQ:AMPH—it offers a great deal for the fundamentals it presents. ↗

January 27, 2025

AMPHASTAR PHARMACEUTICALS IN has caught the attention as a great value stock. NASDAQ:AMPH excels in profitability, solvency, and liquidity, all while being very reasonably priced.

Via Chartmill

Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 08, 2025

Via ACCESSWIRE

NASDAQ:AMPH is an undervalued gem with solid fundamentals. ↗

January 06, 2025

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

November 26, 2024

Via ACCESSWIRE

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.